Continuous positive airway pressure treatment reduces depression symptoms in patients with coexisting obstructive sleep apnea and cardiovascular disease.
In this single-center, prospective, cross-sectional cohort study, the authors aimed to compare the efficacy of zolpidem to melatonin in the treatment of hospital-related insomnia.
The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance.
Simple tweaks to eating and sleeping patterns of “night owls” can lead to significant improvements in sleep/wake timing.
Stimulus control and sleep restriction therapy more effective than multiple-component treatments
Smoking may be related to the severity of obstructive sleep apnea.
A recent study produced normative values for sleep data in healthy adults, which may help aid in future research.
A new Boxed Warning will be required in the prescribing information for several insomnia medications following reports of serious injuries and deaths associated with complex sleep behaviors where patients engaged in activities while not fully awake.
The FDA has approved Sunosi to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or OSA.
Older adults who are witnessed to have sleep apnea have increased accumulations of tau in the entorhinal cortex.